|
|
| Line 3: |
Line 3: |
| {{CMG}}; {{AE}} {{Ammu}} | | {{CMG}}; {{AE}} {{Ammu}} |
| ==Overview== | | ==Overview== |
| According to the American Society of Clinical Oncology, surveillance for medullary thyroid cancer by annual measurement of [[Calcitonin|serum calcitonin]], [[Calcium|serum calcium]], [[parathyroid hormone| serum parathyroid hormone]], and catacholamines is recommended postsurgically to monitor for recurrence and complications for medullary thyroid cancer.
| | There are no established measures for the primary prevention of medullary thyroid cancer. |
| ==Prevention== | | ==Primary Prevention== |
| * According to the American Society of Clinical Oncology, surveillance for medullary thyroid cancer by annual measurement of serum [[calcitonin]], serum [[calcium]], serum [[parathyroid hormone]], and catacholamines is recommended postsurgically to monitor for recurrence and complications for medullary thyroid cancer.
| | There are no established measures for the primary prevention of medullary thyroid cancer. |
| {| style="border: 2px solid #DCDCDC; font-size: 90%; width: 60%;" align=left
| |
| ! style="padding: 0 5px; font-size: 120%; background: #4479BA" align=left| ''{{fontcolor|#FFF| Surveillance of medullary thyroid cancer}}''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left| '''Serum [[calcium]] level annually for people diagnosed with multiple endocrine neoplasia type 2A'''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''Recurrent or residual [[medullary thyroid cancer]] post [[thyroidectomy]] is detected by measurement of serum [[calcitonin]] annually'''
| |
| |-
| |
| | style="padding: 5px 5px; background: #F5F5F5;" colspan="2"|<small>Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/<ref>{{Cite journal| author = [[Jessica Marquard]] & [[Charis Eng]]
| |
| | title = Multiple Endocrine Neoplasia Type 2
| |
| | year = 1993
| |
| | month =
| |
| | pmid = 020301434
| |
| }}</ref>
| |
| |}
| |
| <br><br><br><br><br><br>
| |
| ==References== | | ==References== |
| {{reflist|2}} | | {{reflist|2}} |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
There are no established measures for the primary prevention of medullary thyroid cancer.
Primary Prevention
There are no established measures for the primary prevention of medullary thyroid cancer.
References
Template:WikiDoc Sources